Mohamed Fawzy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Fawzy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abdelrahman G. Ramadan
Assiut University Hospital, Assiut, Egypt
1 shared publication - Abdelrahman Goda
Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt
1 shared publication - Ali Farrag ElHadad
Department of Neuropsychiatry, Al Azhar University, Faculty of Medicine, Assiut, Egypt
1 shared publication - Eman Mohamed Khedr
Assiut University
1 shared publication - Marwa Kh. Mohammed
Assiut University, Assiut, Egypt
1 shared publication - Nagwa M. Ghandour
Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
1 shared publication
Latest Publications
- 16 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 177, 110904
Pediatric functional seizures: Demographics, clinical and psychological characteristics and risk factors
- 16 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 177, 110904
Pediatric functional seizures: Demographics, clinical and psychological characteristics and risk factors
- Open Access
- 19 January 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-13
Heightened excitability and impaired Inhibition in methamphetamine users: a pilot study of neurophysiological correlates of psychological symptoms
Background: In this study, we investigated transcranial magnetic stimulation (TMS)-derived markers of excitability and inhibition in methamphetamine (METH) use disorder. Methods: Sixteen methamphetamine users and 20 matched controls underwent psychological assessments, revised form of Symptom Checklist-90-Revised, cognitive assessment, anxiety and depression scales and TMS measures, including resting and active motor thresholds (RMT and AMT), motor evoked potential amplitude (MEP-A), cortical silent period (CSP), and short-interval intracortical inhibition (SICI). Results: METH users reported higher anxiety, depression, and somatization ( p < 0.001), while cognition remained preserved. They exhibited reduced RMT and AMT ( p < 0.001), indicating increased excitability, with no significant differences in MEP-A ( p = 0.083). CSP onset latency was prolonged at 150% RMT ( p = 0.042), suggesting impaired inhibition. Excitability thresholds correlated negatively with methamphetamine dose, while addiction duration was linked to CSP changes and obsessive-compulsive symptoms. Lower thresholds also correlated with greater interpersonal sensitivity and addiction severity. Conclusion: Increased cortical excitability and decreased inhibitory control are linked to METH usage, and these factors may be underlying psychiatric symptoms. TMS-derived indices show potential as biomarkers for neurophysiological monitoring and targeted interventions in methamphetamine use disorder.
- 19 January 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-13
Open AccessHeightened excitability and impaired Inhibition in methamphetamine users: a pilot study of neurophysiological correlates of psychological symptoms
Background: In this study, we investigated transcranial magnetic stimulation (TMS)-derived markers of excitability and inhibition in methamphetamine (METH) use disorder. Methods: Sixteen methamphetamine users and 20 matched controls underwent psychological assessments, revised form of Symptom Checklist-90-Revised, cognitive assessment, anxiety and depression scales and TMS measures, including resting and active motor thresholds (RMT and AMT), motor evoked potential amplitude (MEP-A), cortical silent period (CSP), and short-interval intracortical inhibition (SICI). Results: METH users reported higher anxiety, depression, and somatization ( p < 0.001), while cognition remained preserved. They exhibited reduced RMT and AMT ( p < 0.001), indicating increased excitability, with no significant differences in MEP-A ( p = 0.083). CSP onset latency was prolonged at 150% RMT ( p = 0.042), suggesting impaired inhibition. Excitability thresholds correlated negatively with methamphetamine dose, while addiction duration was linked to CSP changes and obsessive-compulsive symptoms. Lower thresholds also correlated with greater interpersonal sensitivity and addiction severity. Conclusion: Increased cortical excitability and decreased inhibitory control are linked to METH usage, and these factors may be underlying psychiatric symptoms. TMS-derived indices show potential as biomarkers for neurophysiological monitoring and targeted interventions in methamphetamine use disorder.
- Open Access
- 30 March 2022
- Published by Springer Nature in Middle East Current Psychiatry
- Vol. 29 (1) , 1-12
Clinical pattern of synthetic cannabinoids users in Upper Egypt: cross-sectional study
Background: There is an expanding use of new psychoactive substances containing synthetic cannabinoids in the last years. This study was conducted to identify the epidemiologic data of acute and chronic toxicity by synthetic cannabinoids in Upper Egypt patients. Results: All cases included in the presenting study were fifty males. Most users of synthetic cannabinoids were in the adolescence and middle age group (15–< 35) representing 68%. Curiosity was the most common motivator for using synthetic cannabinoids. Alteration of perception was reported in 68% of subjects after synthetic cannabinoids use. Additionally, dizziness, loss of consciousness, convulsion, and panic attacks were also reported. Cardiovascular adverse effects experienced by users were palpitations (76%) and chest pain (12%). Half of included subjects (50%) reported financial problems and about one-third (32%) got involved in domestic violence. Abnormal routine laboratory findings that were found in included cases were in the form of 12% anemia, 10% leukocytosis, and 6% leucopenia. Also, liver and kidney functions were elevated in 8% and 4% of the cases, respectively. While 22% and 4% of cases were positive for hepatitis C and HIV respectively. Conclusions: This study can be concluded that adolescence are the most common users of SCs; neuro-psychiatric and cardiovascular side effects were the most experienced by subjects. Violence in many forms, especially domestic violence, was associated with synthetic cannabinoids abuse. Trial registration: Registered in clinical trial under name syntheticcannabinoidsAssiut and ID NCT03866941 and URL.
- 30 March 2022
- Published by Springer Nature in Middle East Current Psychiatry
- Vol. 29 (1) , 1-12
Open AccessClinical pattern of synthetic cannabinoids users in Upper Egypt: cross-sectional study
Background: There is an expanding use of new psychoactive substances containing synthetic cannabinoids in the last years. This study was conducted to identify the epidemiologic data of acute and chronic toxicity by synthetic cannabinoids in Upper Egypt patients. Results: All cases included in the presenting study were fifty males. Most users of synthetic cannabinoids were in the adolescence and middle age group (15–< 35) representing 68%. Curiosity was the most common motivator for using synthetic cannabinoids. Alteration of perception was reported in 68% of subjects after synthetic cannabinoids use. Additionally, dizziness, loss of consciousness, convulsion, and panic attacks were also reported. Cardiovascular adverse effects experienced by users were palpitations (76%) and chest pain (12%). Half of included subjects (50%) reported financial problems and about one-third (32%) got involved in domestic violence. Abnormal routine laboratory findings that were found in included cases were in the form of 12% anemia, 10% leukocytosis, and 6% leucopenia. Also, liver and kidney functions were elevated in 8% and 4% of the cases, respectively. While 22% and 4% of cases were positive for hepatitis C and HIV respectively. Conclusions: This study can be concluded that adolescence are the most common users of SCs; neuro-psychiatric and cardiovascular side effects were the most experienced by subjects. Violence in many forms, especially domestic violence, was associated with synthetic cannabinoids abuse. Trial registration: Registered in clinical trial under name syntheticcannabinoidsAssiut and ID NCT03866941 and URL.